Xu W, Li DF, Sun Y, et al. - Via this meta-analysis of relevant published reports, researchers focused on the activity as well as safety of daratumumab added to standard of care, and on the relative efficacy of DRd vs DVMP and other regimens on survival endpoints for untreated myeloma. They identified a total of 6 daratumumab trials with 5,106 individuals. A significantly improved progression free survival (PFS) was provided by daratumumab added to standard of care. Significant PFS advantage was also offered by DRd regimen, compared with other first-line treatments (VMP, Rd, MPT, MP); as well as by DVMP regimen compared with VMP, MPT, MP, in the network meta-analysis for patients ineligible for autologous stem cell transplantation (ASCT). Overall, clinical benefits of daratumumab added to standard of care were seen in newly diagnosed patients with multiple myeloma. For cases ineligible for ASCT, DRd and DVMP could represent good combination choices.